Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating after the ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...

Gilead Sciences ( (GILD) ) has released its Q3 earnings. Here is a breakdown of the information Gilead Sciences presented to its investors.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

Goldman Sachs & Company, Inc. Matt Biegler; Analyst; Oppenheimer and Co. Good afternoon, everyone, and welcome to Gilead's third-quarter 2024 earnings conference call. My name is Rebecca and I'll ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Gilead Sciences Inc (NASDAQ:GILD) reported a strong quarter with a 9% growth in HIV sales year-over-year, driven by higher demand and pricing. The company increased its 2024 guidance across ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. “Gilead’s third quarter results are the strongest o ...

Gilead Sciences, Inc. (NASDAQ:GILD) has received accelerated ... GILD), increasing the biopharmaceutical company's price target to $85 from the previous $80. The ...

Goldman Sachs & Company, Inc. Matt Biegler; Analyst; Oppenheimer and Co. Good afternoon, everyone, and welcome to Gilead's third-quarter 2024 earnings conference call. My name is Rebecca and I'll be ...